First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Overview of attention for article published in Frontiers in Pharmacology, December 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review

Article in Cancers (February 2024)

Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States

Article in Frontiers in Pharmacology (February 2024)

First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis

Article in Therapeutic Advances in Medical Oncology (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.